Predicting mortality and detecting severe disease

Details Predicting mortality and detecting severe disease Predicting mortality and detecting severe disease

2011-08-16

2011-08-16

Cheu, Jacob (Department: 1641)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C436S516000, C436S518000

Reexamination Certificate

active

07998683

ABSTRACT:
Measurement of circulating ST2 and/or IL-33 concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of severe disease.

REFERENCES:
patent: 5786163 (1998-07-01), Hall
patent: 6040147 (2000-03-01), Ridker et al.
patent: 6210976 (2001-04-01), Sabbadini et al.
patent: 6288218 (2001-09-01), Levinson
patent: 6323334 (2001-11-01), Kingsbury et al.
patent: 6905827 (2005-06-01), Wohlgemuth et al.
patent: 7087396 (2006-08-01), Tominaga et al.
patent: 7432060 (2008-10-01), Lee
patent: 2003/0124624 (2003-07-01), Tominaga et al.
patent: 2003/0228570 (2003-12-01), Yat Wah Tom et al.
patent: 2004/0048286 (2004-03-01), Lee
patent: 2004/0133079 (2004-07-01), Mazar et al.
patent: 2005/0130136 (2005-06-01), Lee
patent: 2005/0203046 (2005-09-01), Schmitz et al.
patent: 2005/0250156 (2005-11-01), Shebuski et al.
patent: 2005/0272054 (2005-12-01), Cargill et al.
patent: 2006/0216755 (2006-09-01), Lee
patent: 2007/0042978 (2007-02-01), Girard et al.
patent: 2007/0248981 (2007-10-01), Snider et al.
patent: 2008/0003199 (2008-01-01), Lee
patent: 2009/0192078 (2009-07-01), Lee
patent: 00/35473 (2000-06-01), None
patent: 00/73498 (2000-12-01), None
patent: 01/70817 (2001-09-01), None
patent: 02/38794 (2002-05-01), None
patent: 2004/056868 (2004-07-01), None
patent: WO03094856 (2005-03-01), None
Anwaruddin et al., “Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study,” J. Am. Coll. Cardiol., 47(1):91-97 (2006).
Baekkevold et al., “Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules,” Am. J. Path., 163(1):69-79 (2003).
Baggish et al., “A validated clinical and biochemical score for the diagnosis of acute heart failure: The ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score,” Am. Heart J. 151:48-54 (2006).
Brint et al., “ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance,” Nat. Immunol., 5(4):373-379 (2004).
Bruneau, “Selective changes in natriuretic peptide and early response gene expression in isolated rat atria following stimulation by stretch or endothelin-1,” Cardiovasc. Res., 28(10):1519-1525 (1994).
Brunner et al., “Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma,” Intensive Care Med., 30(7):1468-1473 (2004).
Dhalla et al., “Measurement of adrenolutin as an oxidation product of catecholamines in plasma,” Mol. Cell. Biochem., 87:85-92 (1989).
Januzzi et al., “Natriuretic peptide testing for the evaluation of critically ill patients with shock in the intensive care unit: a prospective cohort study,” Crit. Care, 10(1):R37 (2006).
Januzzi et al., “NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study,” Eur. Heart J., 27(3):330-337 (2006).
Januzzi et al., “The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study,” Am. J. Cardiol., 95(8):948-954 (2005).
Januzzi et al., “Utility of amino-terminal pro-brain natriuretic Peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department,” Arch. Intern. Med., 166(3):315-320 (2006).
Kieser et al., “Identification of the primary growth response gene, ST2/T1, as a gene whose expression is differentially regulated by different protein kinase C isozymes,” FEBS Lett., 372(2-3):189-193 (1995).
Knudsen et al., “Predictors of elevated B-type natriuretic peptide concentrations in dyspneic patients without heart failure: an analysis from the breathing not properly multinational study,” Ann. Emerg. Med., 45(6):573-580 (2005).
Krauser et al., “Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy,” Am. Heart J., 149(4):744-750 (2005).
Kumar et al., “ST2/T1 protein functionally binds to two secreted proteins from Balb/c 3T3 and human umbilical vein endothelial cells but does not bind interleukin 1,” J. Biol. Chem., 270(46):27905-27913 (1995).
Kuroiwa et al., “Construction of ELISA system to quantify human ST2 protein in sera of patients. Hybridoma,” 19(2):151-159 (2000).
Lohning et al., “T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function,” Proc. Natl. Acad. Sci. U.S.A., 95(12):6930-6935 (1998).
Maisel et al., “Bedside B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure With Reduced or Preserved Ejection Fraction,” J. Am. Coll. Cardiol., 41:2010—7i (2003).
Maisel et al., “Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure,” N. Engl. J. Med., 347(3):161-167 (2002).
Maisel et al., “Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath,” J. Am. Coll. Cardiol., 44(6):1328-1333 (2004).
McCord et al., “Relationship between obesity and B-type natriuretic peptide levels,” Arch. Intern. Med., 164(20):2247-2252 (2004).
McCullough et al., “B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study,” Am. J. Kidney Dis., 41(3):571-579 (2003).
Moe et al., “Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan,” Am. Heart. J., 139:587-95 (2000).
Oshikawa et al., “Acute eosinophilic pneumonia with increased soluble ST2 in serum and bronchoalveolar lavage fluid,” Respir. Med., 95(6):532-533 (2001).
Oshikawa et al., “Expression and function of the ST2 gene in a murine model of allergic airway inflammation,” Clin. Exp. Allergy, 32(10):1520-1526 (2002).
Oshikawa et al., “Expression of ST2 in helper T lymphocytes of malignant pleural effusions,” Am. J. Respir. Crit. Care Med., 165(7):1005-1009 (2002).
Oshikawa et al., “ST2 protein induced by inflammatory stimuli can modulate acute lung inflammation,” Biochem. Biophys. Res. Commun., 299(1):18-24 (2002).
Oshikawa et al., “Elevated soluble ST2 Protein Levels in Sera of Patients with Asthma with an Acute Exacerbation,” Am. J. Respir. Crit. Care Med. 164:277-281 (2001).
Sabatine et al., “Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide,” Circulation, 105(15):1760-1763 (2002).
Schmitz et al., “IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines,” Immunity, 23(5):479-490 (2005).
Shimizu et al., “Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis,” Hum. Mol. Genet., 14(19):2919-2927 (2005).
Shimpo et al., “Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction” Circulation, 109(18):2186-2190 (2004).
Strunk et al., “Impact of the history of congestive heart failure on the utility of B-type natriuretic peptide in the emergency diagnosis of heart failure: resu

Affiliated with

Also associated with

Rating

Predicting mortality and detecting severe disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Predicting mortality and detecting severe disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Predicting mortality and detecting severe disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2778218